Evolus (EOLS) AI Stock Analysis

• Market Cap: $381.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: 17.15%
• EPS Growth: -7.23%
• Country: US
• Employees: 372
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.25
• Shares Outstanding: 64,685,420
• 10 Day Avg. Volume: 3,057,355
• 30 Day Avg. Volume: 1,562,514
• PEG Ratio: 0.54
• Price to Book (P/B): 123.99
• Price to Sales (P/S): 2.57
• P/FCF Ratio: -35.16
• Enterprise Value/Market Cap: 1.80
• Enterprise Value/Revenue: 2.48
• Enterprise Value/Gross Profit: 3.71
• Enterprise Value/Ebitda: -13.18
• 1Y Price Target: $19.40
• Price Target Upside: 228.81% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 41 Neutral
• Price Target: $6.00 ▲(1.69% Upside)

Evolus faces significant financial challenges, with negative profitability and reliance on external financing being the most critical issues. Technical indicators suggest bearish momentum. Despite some positive developments in product launches and international expansion, the overall outlook remains cautious.

Positive Factors

Financial Strategy

The company plans to conduct strategic cost structure optimization to save at least $25M in operating expense for 2025 and expects to achieve meaningful profitability in 4Q25 and annual profitability beginning in 2026.

Market Position

Jeuveau continues to maintain a 14% market share, so the company has not seen an impact on its competitive positioning.

Product Launch

There is a positive outlook for the exciting new launch of a second product line with Evolysse.

Negative Factors

Demand Challenges

Deteriorating demand for aesthetics caught up with Jeuveau, leading to lower purchase volumes.

Financial Performance

The company reset 2025 net revenue guidance to $295-$305M from previously guided $345-$355M, with the new guide representing 11%-15% growth, down from the prior guide's 30%-33% growth.

Macroeconomic Factors

Continued tariff threats and negative macroeconomic factors are expected to weigh on consumer sentiment and aesthetics demand.

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc. is a performance-based aesthetic company focused on delivering innovative, non-surgical aesthetic solutions to enhance beauty and confidence. The company primarily operates in the medical aesthetics sector and offers products designed to address the needs of consumers and healthcare providers. Evolus is known for its flagship product, Jeuveau, a botulinum toxin type A injectable treatment aimed at reducing the appearance of glabellar lines, commonly known as frown lines. The company focuses on providing advanced aesthetic technologies that cater to a growing market of consumers seeking non-invasive aesthetic treatments.

How the Company Makes Money

Evolus generates revenue primarily through the sale of its aesthetic products, with Jeuveau being its main source of income. The company employs a business model that includes direct sales to licensed healthcare professionals and partnerships with aesthetic clinics. Revenue is driven by product sales and the establishment of distribution agreements with various medical aesthetic providers. Additionally, Evolus invests in marketing and promotional campaigns to raise awareness of its products among consumers and practitioners, further enhancing its sales potential. The company's focus on innovation and the expansion of its product portfolio plays a significant role in driving revenue growth and sustaining its competitive edge in the market.

Evolus Financial Statement Overview

Summary

Evolus shows revenue growth but faces financial challenges, including negative profitability, deficits in equity, and reliance on external financing. The company needs to improve operational efficiency and financial stability.

Income Statement

Evolus has shown steady revenue growth with a notable increase in total revenue from $56.54M in 2020 to $275.02M in the TTM period ending March 2025. Despite this, the company continues to operate at a net loss, with consistently negative EBIT and EBITDA margins. The net profit margin remains negative, indicating ongoing profitability challenges.

Balance Sheet

The balance sheet reflects significant financial instability, with negative stockholders' equity in recent periods, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, but the overall liabilities exceed assets, pointing to financial leverage concerns. This highlights a need for improved capitalization and risk management.

Cash Flow

Cash flow from operations is consistently negative, although the company has managed to reduce its cash outflows over time. The free cash flow remains negative, suggesting ongoing challenges in generating cash from operations. The company's reliance on financing activities to manage liquidity is evident.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	276.81M	266.27M	202.09M	148.62M	99.67M	56.54M
Gross Profit	185.18M	182.30M	140.53M	92.73M	56.14M	38.24M
EBITDA	-52.17M	-25.00M	-41.81M	-60.72M	-39.06M	-144.75M
Net Income	-61.99M	-50.42M	-61.69M	-74.41M	-46.81M	-163.01M
Balance Sheet
Total Assets	228.80M	232.57M	189.00M	177.98M	257.48M	209.07M
Cash, Cash Equivalents and Short-Term Investments	61.74M	86.95M	62.84M	53.92M	146.26M	107.56M
Total Debt	183.40M	129.98M	126.55M	73.20M	74.74M	138.32M
Total Liabilities	247.46M	227.05M	209.69M	159.48M	175.61M	282.03M
Stockholders Equity	-18.65M	5.52M	-20.69M	18.50M	-422.88M	-376.07M
Cash Flow
Free Cash Flow	-17.21M	-19.47M	-35.63M	-11.71M	-34.36M	-61.01M
Operating Cash Flow	-16.55M	-18.00M	-34.01M	-8.77M	-33.39M	-57.87M
Investing Cash Flow	-4.63M	-4.82M	-1.63M	-1.39M	4.03M	12.19M
Financing Cash Flow	-4.36M	47.41M	44.64M	-1.52M	73.05M	38.35M

Evolus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Negative. The current price of 5.9 is below the 20-day moving average (MA) of 8.80, below the 50-day MA of 9.25, and below the 200-day MA of 11.67, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 15.63 is Positive, neither overbought nor oversold. The STOCH value of 6.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOLS.

Evolus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	82 Outperform	$641.59M	7.80	43.61%	10.13%	3.86%	-2.60%
COLL	75 Outperform	$1.10B	33.72	16.16%	―	22.61%	-63.00%
AVDL	60 Neutral	$1.24B	―	-3.63%	―	132.35%	97.34%
ORGO	51 Neutral	$577.84M	928.57	-2.64%	―	-4.21%	7.78%
Sector *	50 Neutral	AU$2.58B	3.65	5.87%	2.72%	36.78%	13.45%
TLRY	50 Neutral	$713.91M	―	-88.27%	―	4.10%	-594.06%
EOLS	41 Neutral	$381.64M	―	-9999.00%	―	17.15%	-7.23%

Evolus Corporate Events

Evolus Appoints New Principal Financial Officer

On August 1, 2025, Evolus appointed David Moatazedi as Principal Financial Officer, while continuing his role as President and CEO, without additional compensation. The company also announced the departure of Chief Marketing Officer Tomoko Yamagishi-Dressler, effective August 22, 2025, with severance benefits as per her employment agreement. Evolus reported a 4% increase in Q2 2025 net revenue to $69.4 million, driven by the successful launch of Evolysse™ and international growth, despite a decline in U.S. aesthetic procedures. The company expects to achieve meaningful profitability by Q4 2025 and aims for $700 million in total net revenue by 2028, leveraging its existing infrastructure and new product launches.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Evolus Announces Board Changes and Director Elections

On June 5, 2025, Evolus, Inc. experienced significant changes in its board of directors as part of a planned transition, with Simone Blank stepping down and Albert White III joining the Audit Committee. Additionally, during the Annual Meeting of Stockholders, David Gill and Albert White III were elected as Class I Directors, Ernst & Young LLP was ratified as the independent accounting firm, and the compensation of the company’s executive officers was approved.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Evolus CFO Sandra Beaver Announces Resignation

On May 27, 2025, Evolus, Inc. announced the voluntary resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025, as she moves to a new opportunity in a private mental health and wellness technology company. The company emphasized that her departure was not due to any disagreements related to its operations or financial practices. CEO David Moatazedi acknowledged Beaver’s contributions to Evolus’ growth and success, noting the company’s strong momentum with recent product launches and record revenues. Evolus has initiated a search for her successor while its experienced finance team ensures a smooth transition.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.